Nicotinamide Riboside and Metabolic Health

Maastricht University Medical Center15 enrolled

Overview

This study will investigate the effects of 6 week Nicotinamide Riboside supplementation (1000 mg/day) on metabolic health in healthy (pre)obese humans. The primary objective will be hepatic and whole body insulin sensitivity. Secondary objectives, to provide information about the underlying mechanism, will be muscle mitochondrial function, brown fat activity, ectopic lipid accumulation, energy metabolism, cardiovascular risk parameters, body composition and acetylcarnitine levels.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Obesity Insulin Resistance

Interventions

Nicotinamide Riboside (Niagen)DIETARY_SUPPLEMENT

PlaceboDIETARY_SUPPLEMENT

Eligibility

Sex: ALLMin age: 45 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Signed informed consent * Caucasian * Males and postmenopausal females * Aged 45-65 years at start of the study * Body mass index (BMI) 27 - 35 kg/m2 * Stable dietary habits (no weight loss or gain \>5kg in the past 3 months) * Sedentary lifestyle (not more than 2 hours of sports per week) Exclusion Criteria: * Type 2 diabetes * Active diseases (cardiovascular, diabetes, liver, kidney, cancer or other) * Contra-indication for MRI * Participation in earlier research or medical examination that included PET/CT scanning * Alcohol consumption of \>2 servings per day * Smoking in the past 6 months

Locations (1)

Maastricht University Medical Centre

Maastricht, Netherlands

Outcomes

Primary Outcomes

Insulin sensitivity: muscle- and liver specific

Hyperinsulinemic euglycemic clamp: Rate of glucose disappearance (Rd) will be calculated by using tracer kinetics.